Hepatocellular carcinoma: Resection vs. transplantation

(Deutsches Aerzteblatt International) Liver transplantation is the gold standard for treating early hepatocellular cancers. Because of the lack of donors, this option is, however, available to a limited degree only. Curative liver resection is an alternative in this setting. Markus B. Schoenberg, Julian N. Bucher, and coauthors investigated whether liver resection can yield results that are comparable to those of liver transplantation.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Hepatocellular carcinoma (HCC) is a very aggressive disease and represents the third leading cause of cancer-related mortality worldwide [1]. Although treatment of HCC has greatly improved over the last decade, most HCC patients are presented with an underlying chronic liver disease and diagnosed only at advanced stages, when they are no longer eligible for curative therapies such as liver resection or transplantation [2]. In these cases, the multi-target tyrosine kinase inhibitor sorafenib is the only FDA-approved first-line systematic therapy, expanding patient median survival from 7.9 to 10.7 months [3 –5].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In this study, we studied the cytotoxic effects of silibinin combined with sorafenib on hepatocellular carcinoma (HCC). The results indicated that silibinin combined with sorafenib potently inhibited the proliferation of various HCC cells and induced significant apoptosis. In an HCC subcutaneous transplantation tumor model, the combination of silibinin and sorafenib significantly suppressed tumor growth compared with monotherapy. As determined by fluorescence staining and Western blots, the combination of the two drugs inhibited the phosphorylation of RAC-alpha serine/threonine-protein kinase (AKT) and signal transducer an...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Conclusions Chemoembolization with PEG embolic agents for HCC is safe and effective, achieving an objective response rate of 85.5%.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
AbstractThe patient was a 50-year-old female with an initial diagnosis of a single hepatocellular carcinoma in liver cirrhosis. The tumor was located in the posterior liver segment (S7) and measured 5  cm with a rapid growth rate and portal invasion. The pre-treatment Child-Pugh (C-P) was grade A (six points). The total prescribed dose of carbon-ion radiotherapy (C-ion RT) was 60 Gy (relative biological effectiveness) given in 4 fractions. Thereafter, tumor shrinkage and rapid decrease of the s erum alpha-fetoprotein level were observed. At 1-year follow-up a new lesion was diagnosed in the left lobe and the unde...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Conclusion: Although the transplant and resection populations differ, occult multifocality is common in transplant explants and similar to the 46% early recurrence rate following partial hepatectomy. These data suggest that noncurative resection often results from occult intrahepatic multifocality present at the time of resection rather than a malignant predisposition of the remnant liver with de novo tumorigenesis.
Source: Annals of Surgery - Category: Surgery Tags: Original Articles Source Type: research
Circulating tumor DNA (ctDNA) analysis has demonstrated excellent specificity and satisfactory sensitivity to detect somatic mutations across many tumor types and particularly in patients with metastatic disease [1,2]. ctDNA detection rate and level primarily depend on tumor burden, proliferation and tumor type [3]. Its clinical use as a theragnostic biomarker for detectingEGFR mutation has been approved in stage IV non-small-cell lung cancer patients, in whom invasive tumor biopsy may be perilous because of limited accessibility and/or pre-existing organ dysfunction (e.g. emphysema). In that regard, biopsies of hepatocell...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Authors: Sidhu SS, Agarwal S, Goyal O, Kishore H, Sidhu S Abstract A 60 year old male, known case of Hepatitis C related cirrhosis was diagnosed with exophytic Hepatocellular carcinoma (size 2.1 x 2.2 cm), Barcelona Clinic Liver Cancer Stage A, on routine surveillance. He refused liver Transplant and underwent laparoscopic segmental resection. Thereafter patient was started on Tablet Sorafenib 400mg twice daily to prevent recurrence of Hepatocellular carcinoma. On 18st post-operative day, patient presented with Hepatic encephalopathy. Routine investigations and MRI Brain were normal; Venous ammonia was high. Sorafe...
Source: Acta Gastro-Enterologica Belgica - Category: Gastroenterology Tags: Acta Gastroenterol Belg Source Type: research
hé Z Abstract More than 9000 laparoscopic liver resections (LLR) are performed worldwide for benign lesions, malignancy (mainly for hepatocellular carcinoma and colorectal cancer liver metastasis), and living donor hepatectomy. Although there is no absolute size criterion, smaller, peripheral lesions (
Source: Magyar Onkologia - Category: Cancer & Oncology Authors: Tags: Magy Onkol Source Type: research
CONCLUSION: The low-risk group of patients with colorectal cancer and unresectable liver-only disease had a 5-year OS rate following liver transplantation similar to that of patients with HCC with lesions within the Milan criteria. PMID: 29532908 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Transplants | Urology & Nephrology